Jason Karlawish op-ed on FDA needing a risk evaluation and mitigation strategy for Alzheimer’s drug lecanemab, STAT

STAT publishes an op-ed by PARC associate Jason Karlawish on FDA needing a risk evaluation and mitigation strategy for Alzheimer’s drug lecanemab. 

Citations:

"The FDA needs a risk evaluation and mitigation strategy for Alzheimer’s drug lecanemab." STAT, J Karlawish, June 16, 2023.